Pharmaceutical go-to-market transformation has become the industry's most urgent priority, yet cross-functional coordination remains pharma's biggest challenge.
A UK market access summit convened by IQVIA brought together pharma and NHS leaders to look at how working more closely – including more outcomes-based deals – could help UK life sciences through Brexit and beyond.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.